The impact of tislelizumab immunotherapy on multiple primary lung cancer presenting as ground-glass nodules: preliminary results analysis from a single-arm, phase II trial
Patients with synchronous multifocal GGNs exhibited poor therapeutic responses to tislelizumab. Immune checkpoint inhibitors (ICIs) may induce PsP in pure GGNs, thereby leading to unnecessary extension of surgical resection, hence ICIs should be applied with caution in clinical management strategies.
Authors
- Shenghui Qin (ORCID: https://orcid.org/0000-0002-0275-133X)
- Xiangning Fu (ORCID: https://orcid.org/0000-0002-2923-2417)
- Rirong Qu (ORCID: https://orcid.org/0000-0002-3334-3304)
- Junfei Wu
- Yixin Cai
- Jing Xiong (ORCID: https://orcid.org/0000-0003-0476-3198)
- Yi Gao (ORCID: https://orcid.org/0000-0003-3019-3520)
Institutions
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1007/s00262-025-04212-y
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Postdoctoral Science Foundation
- Tongji University